Alirocumab Market Trends Supporting 10.6% CAGR Growth Through 2030
Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Alirocumab Market Expansion Outlook: What Revenue Opportunities Are Ahead?
The alirocumab market has experienced significant expansion recently. Its projected growth will take it from $2.1 billion in 2025 to $2.32 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.4%. Historically, this expansion has been driven by factors such as an increase in LDL cholesterol prevalence, the growing burden of cardiovascular disease, limitations associated with statin therapy, the initial adoption of biologics in lipid management, and progress in clinical guidelines for hypercholesterolemia.
The alirocumab market is projected to experience substantial expansion in the coming years, reaching $3.48 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.6%. This anticipated expansion over the forecast period is primarily driven by factors such as the increasing global elderly population, the growing pipeline of PCSK9 inhibitors, enhanced reimbursement coverage for biologics, the rise of home-based self-administration treatments, and the broader implementation of cardiovascular preventive care initiatives. Key developments anticipated during this period include a greater uptake of PCSK9 inhibitor therapies, an increase in patients with statin intolerance, the expansion of cardiovascular risk screening programs, the development of monoclonal antibody-based lipid-lowering treatments, and a heightened demand for combination lipid-lowering regimens.
Get A Free Sample Report With In-Depth Market Insights:
Alirocumab Market Growth Factors Behind Sustained Expansion
The alirocumab market is poised for growth, primarily driven by the escalating prevalence of cardiovascular diseases. These diseases represent a collection of disorders affecting the heart and blood vessels, including conditions like coronary artery disease, cerebrovascular disease, and heart failure, which together impede the effective circulation of blood and oxygen throughout the body. A key factor behind this rising prevalence is the widespread embrace of sedentary lifestyles, as reduced physical activity contributes to metabolic dysfunction, promotes excess body fat accumulation, and accelerates the development of risk conditions such as hypertension and dyslipidemia, thereby significantly increasing the long-term likelihood of cardiovascular complications. Alirocumab functions by effectively lowering low-density lipoprotein cholesterol levels through proprotein convertase subtilisin or kexin type 9 inhibition, thus helping to mitigate cardiovascular risk and manage disease progression in populations increasingly grappling with these conditions. For instance, in June 2024, according to the data published by the American Heart Association Inc., a US-based non-profit organization, the prevalence of cardiovascular disease in the United States is projected to rise from approximately 50% of adults currently to 61% by 2050. This demonstrates why the increasing prevalence of cardiovascular diseases is driving the growth of the alirocumab market.
Alirocumab Market Segment Breakdown: Which Categories Lead On Revenue?
The alirocumab market covered in this report is segmented –
1) By Indication: Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, Secondary Hyperlipidemia, High Cardiovascular Risk Patients
2) By Administration Route: Subcutaneous Injection, Self-Administration
3) By Patient Demographics: Geriatric, Pediatric, Gender-Based
4) By Treatment Line: First-Line Treatment, Second-Line Treatment
5) By Distribution Channel: Hospitals, Clinics, Online Pharmacies, Retail Pharmacies, Other Distribution Channels
Subsegments:
1) By Familial Hypercholesterolemia: Heterozygous Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia
2) By Atherosclerotic Cardiovascular Disease: Coronary Artery Disease, Peripheral Artery Disease, Cerebrovascular Disease
3) By Secondary Hyperlipidemia: Diabetes Induced Hyperlipidemia, Obesity Related Hyperlipidemia, Hypothyroidism Induced Hyperlipidemia
4) By High Cardiovascular Risk Patients: Hypertension Patients, Smokers At Risk, Elderly Population At Risk, Metabolic Syndrome Patients
Alirocumab Market Industry Trends Fueling Future Revenue Growth
Leading companies in the alirocumab market are focusing on developing innovative products, such as expanded indication biologics, to broaden patient eligibility and enhance early-stage disease management. An expanded indication biologic refers to a therapeutic agent that receives regulatory approval for use in additional patient populations or disease conditions beyond its original indication. For instance, in March 2024, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, announced U. S. Food and Drug Administration approval for Praluent. This development extends the use of alirocumab to pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia, enabling earlier intervention in genetically predisposed individuals. The approval strengthens preventive cardiovascular care by improving low-density lipoprotein cholesterol management and expanding the therapy’s clinical and commercial scope.
Alirocumab Market Key Participants And Competitive Landscape
Major companies operating in the alirocumab market are Sanofi S. A., Regeneron Pharmaceuticals Inc.
View The Full Alirocumab Market Report:
Alirocumab Market Geographic Analysis: Where Is Demand Accelerating Fastest?
North America was the largest region in the alirocumab market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alirocumab market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
